Anticoagulation after pulmonary vein isolation for atrial fibrillation: Associations with CHA₂DS₂-VASc score, sex, and rhythm

J Cardiovasc Electrophysiol. 2023 Mar;34(3):765-768. doi: 10.1111/jce.15848. Epub 2023 Feb 7.

Abstract

Guidelines recommend using the CHA₂DS₂-VASc score to determine anticoagulation decisions in atrial fibrillation (AF) patients, including those who undergo pulmonary vein isolation (PVI), however this may not consistently occur in the real-world setting because of other clinical factors. We sought to evaluate the anticoagulation prescription rates patterns in AF patients 1 year PVI at our institution. Consecutive AF patients undergoing PVI in our prospective registry during 2014-2018 who were alive at 1-year post-PVI were studied. Anticoagulation prescription rates at this time-point were adjudicated, and correlated to CHA₂DS₂-VASc score, sex, and heart rhythm status at 1 year. Amongst 4596 patients undergoing PVI, mean age was 64.2 ± 10.0 years, 1328 (28.9%) were female, and based on CHA₂DS₂-VASc score anticoagulation was not indicated, can be considered and indicated in 872 (19.0%), 1183 (25.7%), and 2541 (55.3%) patients, respectively. At 1-year after PVI, 3504 (76.2%) patients were on anticoagulation, and 792 (17.2%) had recurrence of AF. Anticoagulation was continued in over half of AF patients without classic CHA₂DS₂-VASc indication particularly in those with AF recurrence and women, while they were mildly under-prescribed in those with indication, especially for those without AF recurrence and men. In a large real world cohort of patients after PVI, anticoagulation prescription is not solely depending on the CHA₂DS₂-VASc score and sex, but also heart rhythm status and other clinical or imaging factors.

Keywords: ablation; anticoagulants; atrial fibrillation; pulmonary vein isolation.

MeSH terms

  • Aged
  • Atrial Fibrillation* / surgery
  • Blood Coagulation
  • Catheter Ablation* / methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Veins* / surgery
  • Recurrence
  • Risk Assessment / methods
  • Treatment Outcome